{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"20.2","value":"41.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"68"}],"units":"Participants"}],"title":"Baseline Mean"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"19.7","value":"46.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"54"}],"units":"Participants"}],"title":"Week 17 n=54"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"20.8","value":"47.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"40"}],"units":"Participants"}],"title":"Week 35 n=40"}],"denoms":[{"counts":[{"groupId":"OG000","value":"68"}],"units":"Participants"}],"description":"Patients who completed nine or more items for the 12-item Cushing's syndrome QoL questionaire were considered evaluable for that assessment. Raw scores were obtained for the 12 items using the following scoring: 1) always or very much, 2) often or quite a bit, 3) sometimes or somewhat, 4) rarely or very little, 5) never or not at all. Then the standardized score, Y, was calculated for each patient as follows: Y = 100\\* (X - n) / n\\*5 - n\\*1) = 100 \\* (X - n) / 4\\*n where X denoted the raw score and n the number of questions answered by the patient. The higher the score, the better the QoL. The best possible standardized score was 100 and the worst possible standardized score was 0","dispersionType":"Standard Deviation","groups":[{"description":"Pasireotide montherapy (0.6 mg bid to 0.9 mg bid) was administered until the biochemical control was achieved and if not achieved, a combination was administered: pasireotide (0.9 mg bid) + cabergoline (0.5 QD to 1 mg QD). Patients were able to add cabergoline at anytime during core and extension","id":"OG000","title":"All Patients"}],"paramType":"MEAN","populationDescription":"Full analysis set","reportingStatus":"POSTED","timeFrame":"Baseline and week 17 and 35","title":"Mean Scores of Cushing QoL Standardized Score at Week 17 and 35","type":"SECONDARY","unitOfMeasure":"scores on a scale"}